President

Morais, Prof.João

Joao Morais

View CV

Past President

30-Tselepis-Alexandros

Alexandros Tselepis

View CV

General Secretary / Treasurer

Teresa Padro

Teresa Padró

View CV

Members

linda

Lina Badimon

View CV

Vittorio Pengo

Vittorio Pengo

View CV

Ana-Bronic

Ana Bronic

View CV

Mojca_2023-09_obrezana

Mojca Božič

View CV

Non-voting members

Ismail-Elalamy

Ismaïl Elalamy

View CV

Joao Morais

Head of Cardiology Division; coordinator of Research Center; and adjunct of Clinical Director; Leiria Hospital Center
• Affiliated Professor, Oporto Medical School
• Member of the General Council, Polytechnic School of Leiria
• Integrated member of the Center for Innovative Care and Health Technology (CiTechCare)
• Advocacy Committee, European Society of Cardiology (ESC)
• Nucleus, Working Group Thrombosis (ESC), ex-officio member
• Executive Board and Councillor for Portugal, European Mediterranean League against Thrombotic Diseases (EMLTD)
• Author e co-author of more than 400 scientific papers, 156 published in “peer-review” journals (30318 citations; h-index 55)
• More than 500 scientific presentations by invitation, in Portugal and abroad
• Founder and chairman of the web educational platform “Challenges in Cardiology”

Alexandros Tselepis

Alexandros D. Tselepis has graduated in Pharmacy from the University of Thessaloniki and in Medicine from the University of Ioannina. He obtained his PhD in Clinical Biochemistry in 1986 from the University of Ioannina, Greece. He continued his research studies as a Postdoctoral Fellow (Fogarty, NIH) at the University of Texas Health Science Center, at San Antonio, USA (1988–1989) as well as taking a sabbatical leave at INSERM U323, Paris (1994-1999, three months each year). After initial appointments as Assistant and Associate Professor, he took up his current position of Professor of Biochemistry–Clinical Chemistry in the University of Ioannina, in 2006. Professor Tselepis is also the Director of the Atherothrombosis Research Centre of the University of Ioannina. His main scientific interests are in the pathophysiology of Atherothrombosis. He has more than 263 publications at international journals and more than 8,000 citations, whereas his current h-index is 46 (Scopus).

Teresa Padró

Dr. Teresa Padro is a senior scientist and head of the research group on “Biomarkers for Cardiovascular Disease” in the Cardiovascular Program-ICCC at the Research Institute of the Hospital Santa Creu i Sant Pau (IR-HSCSP) in Barcelona (Spain). Previous positions included research scientist at the Münster-University (Medical School) in Germany and post-doctoral fellow at the Gaubius-Institute-TNO (Netherlands). Dr. Padro research interest focuses on vascular and cardiac disease pathology, coronary microcirculation, atherosclerosis, and thrombosis, with a research career oriented towards translational studies (from bench-to-bedside) aimed to identify new biomarkers or/and molecular targets with potential use in prevention, disease diagnosis, and treatment. Dr Padro expertise in the cardiovascular field is endorsed by more than 140 original articles and reviews (times-cited: 4,879; H-index: 36). Dr. Padro is General Secretary of the EMLTD since 2016 and Chairperson-Elect for the Working Group on Microcirculation and Coronary Pathophysiology (2020-2022) of the European Society of Cardiology.

Lina Badimon

Prof. Lina Badimon is the Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona, Professor at the National Research Council of Spain (CSIC), and Director of the UNESCO Chair in Biomedical Sciences Training and Research. She is Visiting Professor of Manchester Metropolitan University. Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease. She has published over 570 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (H-index: 84. Number of citations: >62,000. ORCID number: 0000-0002-9162-2459). She has written more of 250 reviews and book chapters.

Prof. Vittorio Pengo M.D. (CV as of November 19, 2022)

Mailing Address: Thrombosis Research Laboratory, via Orus 2/B, 35129 Padova, Italy
Tel. +39 49 8212377  e-mail: vittorio.pengo@unipd.it

 

M.D. degree University of Padova 1974
Residency Internal Medicine, University of Padova
Certification Internal Medicine 1980

Cardiology 1985

Post Graduate training Clinical Medicine 1974-1983

Research Fellow, Cardeza Foundation, Philadelphia, PA, USA 1984-1985

Visiting scientist, Cardeza Foundation, Philadelphia, PA, USA, 1988

Clinical Cardiology 1988-

Clinical Interests Primary/secondary prevention and treatment of venous and arterial thromboembolism
Research Interests Pathophysiology and treatment of thrombosis.
Professional activity Professor of Cardiovascular Medicine, Department of Cardiac Thoracic and Vascular Sciences,
and Director of Thrombosis Center, University of Padova School of Medicine, Padova Italy (1988-2019)
Senior Scientist University of Padova and Arianna Foundation on Anticoagulation (2019-)

Reference Lab of APS action America (2014-)

Study awards - scholarships - grants -Study Award on "Coagulation and Liver Diseases" arranged by the University of Padua. AA 1981-1982.

- Two-year scholarship (1984-1985) for studies on: "Calciparin and secondary prevention of heart attack" arranged by Italfarmaco SpA and accepted by the Institute of Clinical Medicine University of Padua.

-Contribution from the Vittorio Tonolli Cultural Foundation for Cardiology for travel expenses to the USA for studies in the field of thrombosis.

- Award of excellence in scientific research in the years 1996-2000 conferred by the University Scientific Commission (area 7). Department Booklet 'Scientific Activity 2000 page 69.

Scientific societies - associations - commissions -Founder of the Italian Association of Anticoagulated Patients (AIPA) (1987)

-Chairman of the National Scientific Committee of the Federation of Associations of Patients on Treatment with Oral Anticoagulants (FEDER-AIPA) from 1995 to 2000.

- Member of the steering committee of the Italian Society of Homostasis and Thrombosis (Siset) 1996

- Member of the editorial board of the journal 'Dialogue on drugs' (1999-2009).

-Component of the European Forum for the study of antiphospholipid antibody syndrome

-President of the Federation of Anticoagulated Surveillance Centers (FCSA) yrs 2000-2003

- Member of the working group of the Ministry of Health for the issuance of guidelines on therapy with oral anticoagulants.

-Chairman of the Scientific Standardization Committee (SSC) on antiphospholipid antibodies 2007-2009

-President of the European and Mediterranean League against Thrombotic Diseases (EMLTD) 2016-2018

 

Reviwer for the following Journals:

New England Journal of Medicine, Circulation, Lancet, Blood, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, Thrombosis Research, American Journal of Cardiology, Haematologica, American Journal of Hematology, Journal of Cardiovascular Medicine, European Journal of Clinical Investigation, European Journal of Internal Medicine, Canadian Medical Association Journal

Associate Editor of Internal and Emergency Journal since 2011

Editorial Board member of Journal of Thrombosis and Haemostasis since 2003

 

Research activity

432 cited documents in International Journals (Scopus)

Total Citations: 20520, H-index: 68 (Scopus).

 

TWENTY MOST CITED PAPERS

 

1 Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism

 Pengo, V., Lensing, A.W.A., Prins, M.H., (...), Iliceto, S., Prandoni, P.     2004     

New England Journal of Medicine 350(22), pp. 2257-2264+2323

 

2

Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)     Palareti, G., Leali, N., Coccheri, S., (...), Berrettini, M., Musolesi, S.       1996      Lancet

348(9025), pp. 423-428

 

3

Update of the guidelines for lupus anticoagulant detection

 Pengo, V., Tripodi, A., Reber, G., (...), Galli, M., De groot, P.G. 2009     

Journal of Thrombosis and Haemostasis 7(10), pp. 1737-1740

 

4

D-dimer testing to determine the duration of anticoagulation therapy Palareti, G., Cosmi, B., Legnani, C., (...), Lensing, A.W.A., Tripodi, A.              2006     

New England Journal of Medicine 355(17), pp. 1780-1789

 

5

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients

 Prandoni, P., Noventa, F., Ghirarduzzi, A., (...), Simioni, P., Pagnan, A. 2007     

Haematologica 92(2), pp. 199-205+III-IV

 

6

The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants               Thiagarajan, P., Pengo, V., Shapiro, S.S.              1986     

Blood 68(4), pp. 869-874

 

7

Chronic thromboembolic pulmonary hypertension

 Kim, N.H., Delcroix, M., Jenkins, D.P., (...), Pengo, V., Mayer, E.             2013     

Journal of the American College of Cardiology 62(25 SUPPL.), pp. D92-D99

 

8

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

 Pengo, V., Ruffatti, A., Legnani, C., (...), Padayattil Jose, S., Iliceto, S.   2010     

Journal of Thrombosis and Haemostasis 8(2), pp. 237-242

 

9

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies    Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., (...), Tektonidou, M., Khamashta, M.          2011     

Lupus 20(2), pp. 206-218

 

10

PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2           Dalla-Volta, S., Palla, A., Santolicandro, A., (...), Marini, M.G., Visani, L.        1992     

Journal of the American College of Cardiology 20(3), pp. 520-526

 

11

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans          Takahashi, H., Wilkinson, G.R., Nutescu, E.A., (...), Kijima, S., Echizen, H.         2006     

Pharmacogenetics and Genomics 16(2), pp. 101-110

 

12

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance             Scordo, M.G., Pengo, V., Spina, E., (...), Gusella, M., Padrini, R.           2002     

Clinical Pharmacology and Therapeutics 72(6), pp. 702-710

 

13

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study

Pengo, V., Ruffatti, A., Legnani, C., (...), Jose, S.P., Iliceto, S.      2011     

Blood 118(17), pp. 4714-4718

 

14

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

 Pengo, V., Denas, G., Zoppellaro, G., (...), Gerosa, M., Banzato, A.         2018     

Blood 132(13), pp. 1365-1371

 

15

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study

 De Laat, B., Pengo, V., Pabinger, I., (...), Mertens, K., De Groot, P.G.     2009     

Journal of Thrombosis and Haemostasis 7(11), pp. 1767-1773

 

16

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review

Open Access

Iorio, A., Kearon, C., Filippucci, E., (...), Siragusa, S., Palareti, G.              2010     

Archives of Internal Medicine 170(19), pp. 1710-1716

 

17

A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy           Palareti, G., Legnani, C., Lee, A., (...), Moia, M., Coccheri, S. 2000     

Thrombosis and Haemostasis 84(5), pp. 805-810

 

18

Antibody profiles for the diagnosis of antiphospholipid syndrome         Pengo, V., Biasiolo, A., Pegoraro, C., (...), Noventa, F., Iliceto, S.       2005     

Thrombosis and Haemostasis 93(6), pp. 1147-1152

 

19

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism         Douketis, J.D., Gu, C.S., Schulman, S., (...), Pengo, V., Prandoni, P.      2007     

Annals of Internal Medicine 147(11), pp. 766-774

 

20

EULAR recommendations for the management of antiphospholipid syndrome in adults

 Tektonidou, M.G., Andreoli, L., Limper, M., (...), Tincani, A., Ward, M.M.          2019     

Annals of the Rheumatic Diseases 78(10), pp. 1296-1304

Ana Bronic

Ana Bronic is Scientific Research Associate with interests in haemostasis, haematology, and molecular diagnostics. Currently employed as specialist in medical biochemistry and laboratory medicine at the Department for laboratory diagnostics in traumatology and orthopaedics.

Clinical Institute of Chemistry, Medical School University Hospital ´Sestre Milosrdnice´, Zagreb, Croatia. She is Head of Working Group for laboratory coagulation in CSMBLM that include continuous work on the development, improvement, and implementation procedures for laboratory haemostasis.

Mojca Božič Mijovski

Mojca Božič Mijovski  is currently head of the Laboratory for Hemostasis and Thrombosis at the University Medical Centre Ljubljana. She is also a lecturer in hemostasis at the University of Ljubljana and a Senior Scientist leading the research group for Laboratory Methodology in Hemostasis and Thrombosis within the Atherosclerosis and Thrombosis Research Program at the Slovenian Research and Innovation Agency.

Profesor Ismaïl Elalamy, M.D. PhD.

Profesor Ismaïl Elalamy, M.D. PhD., is a Professor of Haematology and Head of the Haematology Department at Tenon University Hospital, Sorbonne University in Paris. Prof Elalamy has been involved in the field of thrombosis and antithrombotic therapies since 1991, and his research interests include improving therapeutic strategies, identifying new biomarkers and the application of novel diagnostic techniques to the clinic. He was a Post-Doc fellow at the Pasteur Institute, Paris, from 1998-2003, Associate Professor of Haematology at the APHP, Paris, from 1998-2008, and has also been Head of a Research Group on Hemostasis and Thrombosis in Cancer since 2005 which is now associated to INSERM UMR S-938. In his current position, Prof Elalamy has established an expert centre for diagnosis and management of Heparin-Induced Thrombocytopenia, and a research centre for thrombotic or bleeding risk stratification (Cancer, Pregnancy or Assisted Reproduction Therapy, Familial Thrombophilia…) with specialized clinical and laboratory activity in platelet studies.